Screening a library of expressed cyclic peptides identified clones that reverse the cytotoxicity of α-synuclein in yeast and Caenorhabditis elegans. The results suggest a new approach for intervention in Parkinson's disease, and perhaps a druggable target.
This is a preview of subscription content, log in via an institution to check access.
References
Overington, J.P., Al-Lazikani, B. & Hopkins, A.L. Nat. Rev. Drug Discov. 5, 993–996 (2006).
Reichert, J.M. Nat. Rev. Drug Discov. 2, 695–702 (2003).
Kritzer, J.A. et al. Nat. Chem. Biol. 5, 655–663 (2009).
Scott, C.P. et al. Chem. Biol. 8, 801–815 (2001).
Spillantini, M.G. et al. Nature 388, 839–840 (1997).
Cooper, A.A. et al. Science 313, 324–328 (2006).
Gaeta, A. & Hider, R.C. Br. J. Pharmacol. 146, 1041–1059 (2005).
Gitler, A.D. et al. Nat. Genet. 41, 308–315 (2009).
Knight, Z.A. & Shokat, K.M. Cell 128, 425–430 (2007).
Kinsella, T.M. et al. J. Biol. Chem. 277, 37512–37518 (2002).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
C.P.S. is an inventor on US patent 7,354,756 entitled "Intein mediated cyclization of peptides."
Rights and permissions
About this article
Cite this article
Scott, C. Taking the chemical out of chemical genetics. Nat Chem Biol 5, 609–610 (2009). https://doi.org/10.1038/nchembio0909-609
Issue Date:
DOI: https://doi.org/10.1038/nchembio0909-609
- Springer Nature America, Inc.